Colloidal bismuth subcitrate evokes adaptive cytoprotection in rat gastric mucosa.
The 6-keto-prostaglandin-F1 alpha content (as the stable break-down product of prostacyclin) of rat antral and fundic gastric, as well as of duodenal mucosa, significantly increases after 1, 5 and 10 mg/kg orally administered colloidal bismuth subcitrate treatment. The results indicate that (i) colloidal bismuth subcitrate-induced stimulation of endogenous prostacyclin content ("adaptive cytoprotection") of rat gastroduodenal mucosa may contribute to its therapeutic effect; (ii) the effect of colloidal bismuth subcitrate is not due exclusively to the bismuth content of the molecule, but seems to be connected with the structure of colloidal bismuth subcitrate itself; (iii) the effect seems to be dose-dependent, showing a dose-response relationship.
Balint
G A
GA
Department of Neurology and Psychiatry, Albert Szent-Györgyi Medical University, Szeged, Hungary.
D015121:6-Ketoprostaglandin F1 alpha / Q000032:analysis / Q000378:metabolism; D000704:Analysis of Variance; D000818:Animals; D000897:Anti-Ulcer Agents / Q000494:pharmacology*; D003102:Colloids; D004386:Duodenum; D011464:Epoprostenol / Q000378:metabolism*; D005260:Female; D005753:Gastric Mucosa / Q000187:drug effects / Q000378:metabolism*; D007413:Intestinal Mucosa / Q000187:drug effects / Q000378:metabolism*; D007700:Kinetics; D009942:Organometallic Compounds / Q000494:pharmacology*; D051381:Rats; D011919:Rats, Inbred Strains; D012016:Reference Values; D013997:Time Factors
D000897:Anti-Ulcer Agents; D003102:Colloids; D009942:Organometallic Compounds; D015121:6-Ketoprostaglandin F1 alpha; D011464:Epoprostenol; C002791:bismuth tripotassium dicitrate